Information Provided By:
Fly News Breaks for May 13, 2019
INSY
May 13, 2019 | 06:19 EDT
Piper Jaffray analyst David Amsellem cut his price target for Insys Therapeutics to $2 from $4 and reiterates an Underweight rating on the shares. The company on Friday night announced that it is facing significant liquidity issues such that it may not be able to continue as a going concern due to estimated liabilities of $240M related to the U.S. Department of Justice investigation and other legal matters, coupled with the continued deterioration of Subsys sales/volumes, Amsellem tells investors in a research note. Perhaps the end game of the federal government is Insys no longer being a going concern, adds the analyst.
News For INSY From the Last 2 Days
There are no results for your query INSY